Layered Double Hydroxide-Loaded Dl-3-n-Butylphthalide Alleviates Renal Ischemia-Reperfusion Injury by Regulating the PI3K-AKT-Nrf2 Signaling Pathway Authors: Yan Yan, Ke Wang, Li Ren, Jun-jie Ma, Xing-chun Zhu, Hao-feng Ding, Jia-xin Chu, Zhi-gao Zhu, Jing-yi Xia, Yi Xia, Yuan Xu, Meng-han He, Wen-rui Wang, Cong-li Zhang Published: 2026 ABSTRACT PurposeThis study aims to address the issues that limit the clinical application of Dl-3-n-butylphthalide (NBP) due to its poor water solubility and low bioavailability, and to explore its therapeutic potential in renal ischemia-reperfusion (I/R) injury. We attempted to utilize layered double hydroxide (LDH) to construct a novel nano-drug delivery system to enhance the stability and efficacy of NBP, and to deeply investigate its potential mechanism of action.MethodsBy loading NBP onto LDH, LDHs-NBP nanocomplexes were successfully constructed. Subsequently, the effects of LDHs-NBP on renal function, tissue pathology, cell apoptosis, oxidative stress and mitochondrial function were systematically evaluated in rat renal ischemia-reperfusion injury models and HK-2 cell hypoxia/reoxygenation models. The molecular mechanism of the PI3K-AKT-Nrf2 signaling pathway was analyzed through immunohistochemistry and Western Blot.ResultsThe experimental results show that the drug loading capacity of LDHs-NBP nanocomplexes is 24.26%. Compared with pure NBP, LDHs-NBP more effectively improve renal function in rats, reduces serum creatinine (SCr) and blood urea nitrogen (BUN), decreases inflammatory infiltration and structural damage in renal tissues, and exhibits stronger antioxidant capacity—evidenced by decreased malondialdehyde (MDA) levels and increased superoxide dismutase (SOD) and total antioxidant capacity (T-AOC) activities. At the cellular level, LDHs-NBP significantly inhibits apoptosis and ROS production in HK-2 cells, alleviates mitochondrial dysfunction, and its protective effect is closely associated with activation of the PI3K-AKT-Nrf2 signaling pathway.ConclusionThis study successfully constructed an NBP nano-complex based on LDH, and confirmed that LDHs-NBP has significant therapeutic advantages in renal ischemia-reperfusion injury. The mechanism may be related to the activation of the PI3K-AKT-Nrf2 pathway. This study provides experimental evidence for the application of LDHs-NBP in the treatment of renal ischemia-reperfusion injury, and shows a promising translational prospect and clinical value. Introduction Acute kidney injury (AKI) resulting from ischemia-reperfusion (I/R) is a frequent complication in surgical procedures, including renal transplantation and major cardiovascular surgeries. Without timely intervention, it may progress to renal failure, renal fibrosis, and chronic kidney disease.1,2 The pathophysiological process of I/R-induced AKI involves multiple interrelated mechanisms, such as inflammatory responses, oxidative stress, mitochondrial dysfunction, and dysregulation of autophagy.3–6 As of now, the clinical strategies for preventing and treating renal I/R injury fall short. Therefore, there is an urgent clinical demand for effective therapeutic agents to treat AKI, making it a major priority in current research efforts. Dl-3-n-butylphthalide (NBP) is a substance coming from celery seeds that has already been verified to have neuroprotective and anti-inflammatory properties and is typically used in the treatment of acute ischemic stroke.7,8 Accumulating evidence has demonstrated that NBP not only attenuates renal I/R injury and delays the progression of hypertensive nephropathy by suppressing excessive inflammation and oxidative stress, but also ameliorates nephropathy through the reduction of pathological fibrosis and podocyte apoptosis.9–12 However, the therapeutic efficacy and clinical application of NBP in kidney diseases are significantly limited by its inherent low water solubility and limited bioavailability. Therefore, improving the bioavailability of NBP and elucidating molecular mechanisms underlying its renoprotective effects could enhance its therapeutic potential in I/R-induced AKI, clarify its molecular targets, and provide a solid theoretical basis for its broader application in kidney-related disorders. Layered double hydroxide (LDH), as a positively charged layered material, exhibits an outstanding anion exchange capacity, enabling the efficient intercalation of various bioactive molecules into their nanoscale interlayer galleries.13 Owing to their favorable biocompatibility, high drug loading capacity, and pH-responsive degradation behavior, LDH demonstrates considerable potential in controlled drug release and targeted delivery.14–17 Nanomaterial-based drug delivery systems have been used more and more in the treatment of kidney diseases.18 Although NBP has shown notable efficacy in the management of ischemic disorders, its clinical application is significantly constrained by inherent physicochemical limitations. Specifically, its low aqueous solubility results in poor oral absorption and reduced bioavailability; moreover, it undergoes rapid metabolism in vivo, which impedes the maintenance of sustained therapeutic plasma concentrations. Consequently, there is a critical need to develop a delivery system capable of simultaneously improving solubility, enhancing stability, and enabling controlled release. Given their advantageous structural properties, LDH serves as a promising nanocarrier platform to address these challenges. Prior research by our team has demonstrated that sorafenib loaded into LDH can suppress the proliferation of hepatic stellate cells in vitro, as well as produce anti-fibrotic effects in vivo.19 At present, there are no reports on the application of LDH combined with NBP preparations in this field. Therefore, we propose the development of an LDH-based drug delivery system for NBP, aiming to enhance its renal accumulation, stability, and overall therapeutic efficacy. This study aims to utilize LDH as a drug delivery carrier to construct a nano-complex, LDHs-NBP, loaded with NBP, with the objective of enhancing its delivery efficiency and therapeutic efficacy, as well as achieving efficient and stable delivery of NBP to renal tissues. In addition, this study systematically explored the protective effect of LDHs-NBP on renal I/R injury and its related molecular mechanisms, aiming to provide potential new therapeutic ideas for intervention in kidney diseases. Materials and Methods Reagents and Antibodies MgCl2·6H2O (97%), AlCl3·6H2O (97%), and NaOH (97%) were purchased from Aladdin Reagent Co., Ltd. DMEM/F12 and FBS were obtained from Procell Life Science & Technology Co., Ltd. The Sprague-Dawley rats were obtained from Jiangsu Qinglongshan Biotechnology Co., Ltd. (license number: SCXK(SU)2024-0001). HK-2 cells were obtained from Cellcook Biotech Co., Ltd. The CCK-8 cell counting kit, BCA protein detection kit, SCr, BUN, ALT, AST, SOD, MDA and T-AOC detection kits were purchased from Nanjing Jiancheng. The apoptosis, ROS, and JC-1 detection kit were obtained from Beyotime Biotechnology. LY294002 was purchased from MedChemExpress while butylphthalide was obtained from Shijiazhuang CSPC-NBP Pharmaceutical Co., Ltd. PI3K (1:1000), p-PI3K (1:1000), AKT (1:1000), p-AKT (1:1000), Nrf2 (1:1000), β-actin (1:10000) were bought from Affinity Biosciences. The ready-to-use trichloroethanol solution (M2820) with a concentration of 2.5% was purchased from Nanjing Aibei Biotechnology Co., Ltd. Animal Grouping and Model Establishment Sixty SPF-grade male SD rats (5–6 weeks old) were housed in a 25 °C SPF animal room, with the relative humidity maintained at 40% to 70%. One week later, they were randomly divided into six groups based on a computer-generated random number sequence, including Sham, I/R, I/R+LDHs, I/R+NBP, I/R+LDHs-NBP, and I/R+LDHs-NBP+LY294002. Each group received daily intraperitoneal injections of normal saline, LDHs (20 mg/kg), NBP (5 mg/kg), or LDHs-NBP (25 mg/kg), administered at equal volumes, for seven consecutive days. To explore the PI3K-AKT pathway, the I/R+LDHs-NBP+LY294002 group rats were injected with LY294002 (10 mg/kg, i.p.) for 30 minutes before the construction of the model. The model was established during 12 hours of fasting: Rats were anesthetized with 2.5% tribromoethanol solution (6 mL/kg). Blood was collected by way of an IVC puncture, and on either side, the renal arteries were separated roughly, then the right kidney was removed. The Sham group exposed the left kidney but did not ligate the left renal artery. In the remaining groups, ischemia was induced by clamping the left kidney artery with non-invasive vascular clips for 45 minutes. After 24 hours of reperfusion, rats were reanesthetized, the left kidney was removed, the blood sample was collected for further analysis. Then, the rats were euthanized with an excessive dose of tribromoethanol. The experiments were approved by the Animal Ethics Committee of Bengbu Medical University. Cell Culture, Group Design, and Model Construction HK-2 cells used in the experiments were cultured at 37 °C. They were assigned to six experimental groups: Control, H/R, H/R+LDHs, H/R+NBP, H/R+LDHs-NBP, H/R+LDHs-NBP+LY294002. Cell confluence reached about 70–80% and then the control group was refreshed with fresh normal medium and was then kept under normoxic conditions for 12 hours. On the other hand, cells of the H/R and treatment groups were transferred to the DMEM/F12 medium without glucose supplemented with the corresponding drug, and kept in hypoxia for 12 hours, then re-oxygenated for 4 hours under normal culture conditions, to establish the H/R model. Synthesis of LDHs and LDHs-NBP Nanoparticles Inorganic nanocarriers were synthesized via the hydrothermal co-precipitation method.19 Briefly, a 40 mL solution of 272 mg NaOH was prepared and placed under N2. Then, a mixed metal salt solution containing 241.4 mg of AlCl3·6H2O and 609.9 mg of MgCl2·6H2O was added dropwise with stirring for 10 mL; The reaction was stirred in a water bath at 60 °C. Resuspended and re-centrifuged. Transfer the pellet into a sealed autoclave for hydrothermal reaction at 100 °C for 16 hours. The product was collected by centrifugation. The harvested product was then redispersed in 2 mL of dd H2O and subjected to freeze-drying. And we obtained the LDHs and stored them at −20 °C. Drug loading: 10 mg of the nanocarrier was dispersed in 80 mL of 20 mg NBP. Incubating on a shaker at 37 °C for 24 hours. The final complex LDHs-NBP was then precipitated with centrifugation (12,000×g for 1 hour), lyophilized, and stored at −20 °C. Characterization of LDHs and LDHs-NBP Drop a diluted solution containing LDHs and LDHs-NBP onto the surface of a carbon-coated copper grid. The samples were imaged, and EDS was conducted on FEI Talos F200X G2 electron microscope (USA). The size distribution and zeta potential at 25 °C were measured with a Malvern analyzer. The molecular structure and composition of LDHs and LDHs-NBP nanocapsules were detected by FTIR on the Thermo Fisher Nicolet iS20 (USA). XRD patterns of samples were obtained for Cu Kα (λ = 1.54060 nm), Rigaku SmartLab SE X-ray diffractometer (Japan), between 5° to 90° with a scan step of 0.0330°. Determination of Drug Loading of LDHs-NBP Use a UV–Vis spectrophotometer to measure the absorbance of NBP in the wavelength range of 200–800 nm to determine its maximum ultraviolet absorption peak. A series of dilutions of the NBP stock solution with pure water was prepared at concentrations of 0.0125, 0.025, 0.0625, 0.125, 0.2, and 0.25 mg/mL, and the absorbance at the wavelength of maximum absorption was recorded to construct a calibration curve. Using the UV spectrophotometer to measure the ultraviolet absorption peak of the supernatant after centrifuging during the synthesis of LDHs-NBP, we substitute it into the standard curve calculation, and then the mass is calculated according to the volume of the supernatant: Drug loading (%) = (mNBP – mNBP in supernatant) / (mLDHs + mNBP – mNBP in supernatant) × 100%, where mNBP is the initial mass of NBP used, mNBP in supernatant is the residual mass of NBP detected in the supernatant post-centrifugation, and mLDHs is the mass of the LDHs carrier added. In vitro Cellular Uptake Analysis FITC-labeled LDHs-NBP was obtained by adding 1 mg LDHs-NBP and 1 mg FITC to 1 mL PBS, then shaking at 4 °C for 24 hours. The suspension was diluted to a concentration of 5 µg/mL using the glucose-free culture media. HK-2 cells were plated at 1×104 cells/well in a confocal dish and cultured till cells were stably adhering and a normal morphology was observed. The medium was replaced with a diluted FITC-LDHs-NBP suspension, and cells were incubated at 0, 1, 4, 12, 24, 36, and 48 hours. At each time point the cells were fixed with paraformaldehyde. Cellular uptake was visualized on a laser scanning confocal microscope (Olympus FV-1200 MPE, Japan). Lysosome Escape and Permeability Experiment Lysosomal escape was evaluated using FITC-labeled LDHs-NBP. The culture medium was then replaced with glucose-free medium containing LDHs-NBP, followed by hypoxic treatment for 12 hours and subsequent reoxygenation for 4 hours. After treatment, cells were incubated with LysoTracker Red in the dark for 2 hours. Then they were counterstained with Hoechst for 15 minutes under light-protected conditions. Excess dye was removed by washing with PBS, then immediately imaged with a Zeiss fluorescence microscope, which has the proper filters for viewing multiple channels. Lysosomal membrane permeability was studied using AO staining. HK-2 cells were inoculated in confocal dishes at 1×104 cells/well and cultured till they adhered and had normal morphology. The culture medium was changed to glucose-free medium containing 5 µg/mL LDHs-NBP, then hypoxic for 12 hours and returned to normoxic conditions for 4 hours. After processing, the cells are incubated with 10 µg/mL AO staining reagent for 15 minutes for staining. They were then fixed by the addition of 400 μL of 4% paraformaldehyde per well for 15 minutes and thoroughly rinsed with PBS. Fluorescence pictures were collected immediately afterward using a fluorescence microscope Zeiss with a filter compatible with two different channels. Cell Proliferation Assay The cells were replated into normal culture medium. Subsequently, 10 μL of CCK8 reagent was added, and then waited for 2 hours as per the manufacturer’s instructions. Cell viability was assessed using the microplate reader by taking the absorbance. ROS and Apoptosis Analysis Cells were treated with the drug and then subjected to 12 hours of hypoxia followed by 4 hours of reoxygenation. Trypsinization, cell suspension, centrifugation, resuspension in PBS+DCFH-DA incubate at room temperature for 30 minutes. Apoptosis was evaluated using the apoptosis kit. After this, the samples were analyzed by flow cytometry using a CytoFLEX instrument (Beckman Coulter) and data were processed with FlowJo software (v10.6.2). Mitochondrial Membrane Potential Analysis Cells were seeded at 1×104 cells per well on the confocal dish. After drug treatment, the cells were subjected to hypoxia for 12 hours and then oxygenation for 4 hours. They were incubated with JC-1 probe for half an hour. Then the cells were imaged on a Zeiss fluorescence microscope. Transmission Electron Microscope Cells after being subjected to drug treatment and hypoxia reoxygenation were fixed with glutaraldehyde and then fixed with osmium tetroxide for 1 hour. They were dehydrated, infiltrated with acetone, and embendded in embedding medium. The sections were stained with 1% aqueous solutions of acetic acid, bismuth uranium, scanned on a transmission electron microscope. Reagent Kit Test The levels of relevant factors in rat kidney tissues and cells, as well as in serum, were determined using specific detection kits. Absorbance was measured at the designated wavelength, and the concentration of each parameter was calculated according to the instructions of the reagent kit. HE Staining The kidney tissue fixed was sectioned and then paraffin-embedded. Ten non-overlapping fields were randomly selected at 200× magnification under the microscope for assessment of renal pathological changes. Select 10 renal tubules from each field, ensuring that no tubule is scored more than once. The degree of kidney injury was judged by three high-level senior physicians from the pathologic department at our hospital according to the Paller scoring criteria, using an optical microscope in a concealed manner, and then the renal tubule score was calculated and averaged. The evaluator is unaware of the grouping situation. Immunohistochemistry The kidney tissue fixed with 4% Paraformaldehyde was sectioned and then paraffin-embedded. The sections were blocked to inhibit, followed by blocking with 10% goat serum. Then, they apply antibodies. DAB was used for staining, and hematoxylin was used for counterstaining and sealing. Finally, each section was photographed using an optical microscope. A blinded observer quantified the ratio of the positive area in each part. The evaluator is unaware of the grouping situation. Transcriptomics and Metabolomics Analysis In the transcriptome sequencing experiment, the tissue was ground into powder, total RNA was extracted from the samples, and subsequently converted into double-stranded cDNA through reverse transcription. After purification, a library is made and sequenced with a gene sequencer. For metabolomics experiments, supernatant was extracted from processed tissues before being used for analysis by Q Exactive HF-X (Thermo Scientific) or an ultra-high-performance liquid chromatography (Thermo Scientific Conquest) machine. A chromatographic column was conducted for computer detection. Western Blot Assay Harvest cells and kidney tissues. Extract total protein using lysis buffer supplemented with protease and phosphatase inhibitors. Quantify protein concentration using the BCA assay. Separate proteins by SDS-PAGE under an electric field, then transfer them onto a PVDF membrane. Block the membrane with a commercial blocking solution, followed by sequential incubation with primary and secondary antibodies. Finally, detect protein signals using a chemiluminescent gel imaging system. Statistical Analysis All data are presented as the mean ± SD. The two-group comparisons were performed using the t-test, while one-way analysis of variance (ANOVA) was applied to assess differences across three or more groups. Data statistical analysis and statistical graph drawing were conducted using GraphPad Prism 10.0. Significant differences are marked as *p < 0.05, **p < 0.01, and ***p < 0.001. Results Characterization of LDHs and LDHs-NBP In this study, the synthesis of Mg-Al-LDHs and LDHs-NBP (Figure 1A) was successfully achieved by the hydrothermal co-precipitation. Characterization results revealed that LDH presented a typical hexagonal layered structure with no morphological changes after loading NBP, suggesting a homogenously distributed NBP within the interlayer regions. Elemental analysis shows that the material has a Mg/Al ratio of about 3:1, which is uniform (Figure 1B). Particle size analysis showed that the average particle diameter increased from 186.8 ± 1.9 nm for pristine LDH to 244.5 ± 6.9 nm after loading with NBP, indicating successful incorporation of the drug into the nanocarrier system. At the same time, it was found that the Zeta potential decreased from 40.8 ± 0.98 mV to 24.3 ± 1.1 mV, the insertion of NBP into LDHs leads to a change in the potential of the composite carrier (Figure 1C). XRD patterns showed that the crystallinity of the original LDH was not destroyed by the introduction of NBP, no new diffraction peaks emerged, which proved that the structure of LDHs-NBP was still maintained (Figure 1D). From Figure 1E of FTIR spectroscopy, we can see that there are typical absorption bands for both LDH and NBP, without any other peaks, which also further indicates the successful load of NBP. Ultraviolet (UV) spectroscopy shows a peak of maximum absorption of the NBP spectrum at 214 nm (Figure 1F). The drug loading capacity of LDH was determined using the calibration curve equation: Y = 0.008475X + 0.01142, R2=0.9919, and it was 24.26% (Figure 1G). We plotted the in vitro release curves of LDHs-NBP under different pH conditions, respectively, simulating the physiological state (pH 7.4) and the pathological state (pH 6.4) (Figure 1H). The results showed that the LDH carrier exhibited pH-responsive sustained-release characteristics. Figure 1(A) Schematic illustration of the synthesis procedures for Mg-Al-LDHs and LDHs-NBP. (B) TEM images (100 nm) and elemental distribution energy spectrum analysis of Mg-Al-LDHs and LDHs-NBP. (C) Particle size and Zeta potential analysis; the PDI is indicated to reflect particle uniformity. (D) XRD of Mg-Al-LDHs, NBP, and LDHs-NBP. (E) FTIR of Mg-Al-LDHs, NBP, and LDHs-NBP. (F) Full-spectrum ultraviolet (UV) absorption scan of NBP. (G) Calibration curve of NBP used for quantitative analysis. (H) The in vitro release curves of LDHs-NBP under different pH conditions.Top panel: A schematic of synthesis. A beaker labeled NaOH Solution receives AlCl3, MgCl2 and DL-3-n-butylphthalide, with N2 shown. Steps show 60°C 1h, then 100°C 16h to form LDHs, then addition of NBP and 37°C 24h to form LDHs-NBP. Second row: TEM images labeled Mg-Al-LDHs and LDHs-NBP, plus elemental maps labeled Mg2+ and Al3+ and merged maps labeled Mg-Al-LDHs and LDHs-NBP. Scale bars include 100 nm and 50 nm. Third row: Part icle size and Zeta potential. Mg-Al-LDHs: Z-Average 187.1nm, Pdi 0.265; Zeta Potential 41.1mV. LDHs-NBP: Z-Average 236.5nm, Pdi 0.158; Zeta Potential 24.6mV. Bottom rows: XRD plot with Intensity (a.u.) versus 2θ (degree) for LDHs, NBP, LDHs-NBP. FTIR plot with Transmittance (percent) versus Wavenumber (cm superscript minus 1) for LDHs, NBP, LDHs-NBP. UV plot with Absorbance versus Wavelength (nm). Calibration curve plot with Absorbance (a.u.) versus NBP (μg/mL). Release plot with Release (percent) versus Time (h) for pH=6.4 and pH=7.4.An infographic on Mg-Al-LDHs and LDHs-NBP synthesis steps and test results. (A) Schematic illustration of the synthesis procedures for Mg-Al-LDHs and LDHs-NBP. (B) TEM images (100 nm) and elemental distribution energy spectrum analysis of Mg-Al-LDHs and LDHs-NBP. (C) Particle size and Zeta potential analysis; the PDI is indicated to reflect particle uniformity. (D) XRD of Mg-Al-LDHs, NBP, and LDHs-NBP. (E) FTIR of Mg-Al-LDHs, NBP, and LDHs-NBP. (F) Full-spectrum ultraviolet (UV) absorption scan of NBP. (G) Calibration curve of NBP used for quantitative analysis. (H) The in vitro release curves of LDHs-NBP under different pH conditions. Drug Safety Assessment and Renal Protective Effects To understand what effects the drugs had and whether they were safe for use, we tested the liver and kidneys. We looked at how the major organs in the rats looked under a microscope 7 days after we gave them the drug (Figure 2A). No significant differences concentrations of SCr, BUN, AST, and ALT were detected between the Sham, LDHs, NBP, and LDHs-NBP treatment groups (Figure 2B). Histopathological examination via HE staining revealed no apparent pathological alterations in the heart, liver, spleen, lung, or kidney across all treatment groups, indicating that both LDHs and LDHs-NBP exhibit favorable biocompatibility and biological safety (Figure 2C). In contrast, HE staining of kidney tissues showed that the I/R group exhibited characteristic signs of renal injury. Treatment with both NBP and LDHs-NBP markedly improved renal histopathological alterations. Notably, the LDHs-NBP group demonstrated a more pronounced protective effect (Figure 2D and E). In comparison to the I/R group, both NBP and LDHs-NBP attenuated the model-induced elevation of SCr and BUN levels, with LDHs-NBP showing superior efficacy relative to NBP monotherapy (Figure 2F). Figure 2(A) Schematic flowchart of the rat experimental model establishment. The red dashed box indicates removal of the right kidney. (B) Serum biochemical indicators of liver and kidney function in rats. (C) HE staining images. Scale bar: 100 μm. (D) Representative HE-stained kidney sections following induction of renal injury. The renal tubular injury is indicated by the black arrow. Scale bar: 100 μm. (E) Paller scoring of renal histopathological. (F) Renal function parameters after establishment of the renal I/R injury model. Data are expressed as mean ± SD (n=3). Statistical significance is denoted as *p < 0.05, and ***p < 0.001.The image A shows a timeline of the experimental procedure on a rat, including abdominal injections from Day 1 to Day 7, ischemia for 45 minutes on Day 8 and sample collection on Day 9. The image B shows four bar graphs displaying serum biochemical indicators: ALT, AST, SCr and BUN across Sham, LDHs, NBP and LDHs-NBP groups. The image C shows HE staining images of heart, liver, spleen, lung and kidney tissues for Sham, LDHs, NBP and LDHs-NBP groups. The image D shows HE-stained kidney sections for Sham, I/R, I/R plus LDHs, I/R plus NBP and I/R plus LDHs-NBP groups. The image E shows a bar graph of Paller scores for renal histopathology across the same groups, with statistical significance indicated. The image F shows two bar graphs of SCr and BUN levels, comparing the same groups, with statistical significance denoted by asterisks.A study on renal injury in rats and the therapeutic effect, including charts and histological images. (A) Schematic flowchart of the rat experimental model establishment. The red dashed box indicates removal of the right kidney. (B) Serum biochemical indicators of liver and kidney function in rats. (C) HE staining images. Scale bar: 100 μm. (D) Representative HE-stained kidney sections following induction of renal injury. The renal tubular injury is indicated by the black arrow. Scale bar: 100 μm. (E) Paller scoring of renal histopathological. (F) Renal function parameters after establishment of the renal I/R injury model. Data are expressed as mean ± SD (n=3). Statistical significance is denoted as *p < 0.05, and ***p < 0.001. Bioinformatics Analysis and Omics Analysis To investigate the mechanism of action of LDHs-NBP, we performed integrated bioinformatics and multi-omics analyses. Through database intersection analysis, six key proteins associated with AKI and NBP were initially identified, including AKT1 and BCL2 (Figure 3A and B). Transcriptomic profiling revealed that, compared with the Sham group, the I/R model induced alterations in gene expression, with 1213 upregulated and 1597 downregulated genes. LDHs-NBP treatment led to an increase of 98 genes and a decrease of 229 in comparison with the I/R group, which showed partial recovery of dysregulated gene expression (Figure 3C). Venn diagram analysis resulted in 61 differentially expressed gene overlaps (Figure 3D and E), and KEGG enrichment analysis indicated that the PI3K-AKT pathway predominated (Figure 3F). Metabolomic analysis showed that compared with the sham group, the I/R group had 646 upregulated metabolites and 407 downregulated metabolites. LDHs-NBP treatments greatly modified 281 metabolites (186 up, 95 down) (Figure 3G), 42 common metabolic modifications were found (Figure 3H and I), which were mostly enriched in the glycerophospholipid metabolism pathway (Figure 3J). Glycerophospholipids are key structural components of cellular membranes and precursor molecules for important signaling molecules. PIP2 is one such essential molecule. PI3K mediates the conversion of PIP2 into PIP3 through phosphorylation, producing a crucial secondary messenger that triggers the activation of downstream AKT signaling pathways. Collectively, the multi-omics data suggest that LDHs-NBP may ameliorate kidney injury by modulating the PI3K-AKT within the glycerophospholipid metabolic pathway. Figure 3(A and B) Gene selection and screening of core genes for the intersection of AKI and NBP genes. (C and D) Venn diagrams of overlapping differentially expressed genes in the three experimental groups, volcano plot of significantly differentially expressed genes between I/R and Sham, and volcano plot of significantly differentially expressed genes between I/R+LDHs-NBP and I/R. (E and F) Heatmap showing significantly differentially expressed genes in different samples and bubble chart of significant pathway enrichment analysis for all significant differentially expressed genes in I/R+LDHs-NBP (vs I/R). (G–J) A Venn diagram identified commonly differentially expressed metabolites across three groups, a heatmap visualized their expression patterns, and a bubble chart displayed significantly enriched pathways in the I/R+LDHs-NBP compared to the I/R.The image A showing a two-circle Venn diagram labeled AKI and NBP with values 993 in AKI only, 7 in the overlap and 10 in NBP only. The image B showing a protein interaction network with nodes IL2, APP, AKT1, NFE2L2, SOD1 and BCL2, connected by multiple lines. The image C showing two volcano plots of differential gene expression. For both plots, x-axis label Log2(Fold Change) (unit unclear) and y-axis label minus Log10(P value) (unit unclear). Top plot statistics: Up 1213, Down 1597, Insignificant 19062. Bottom plot statistics: Up 98, Down 229, Insignificant 19062. The image D showing a four-set Venn diagram labeled Up I/R+LDHs-NBP vs I/R, Down I/R+LDHs-NBP vs I/R, Down I/R vs Sham, Up I/R vs Sham, with visible region values 53, 173, 39, 1151, 1558, 22, 23, 17 and multiple regions labeled 0 (some overlap values unclear). The image E showing a clustered heatmap of significantly differentially expressed genes with a Group legend listing Sham, I/R and I/R+LDHs-NBP and a value scale from negative 2 to positive 2 (unit unclear). The image F showing a pathway enrichment bubble chart. x-axis label Rich Factor (unit unclear) with ticks 0.03, 0.04, 0.05, 0.06, 0.07. y-axis labels: Calcium signaling pathway; Rap1 signaling pathway; Gap junction; Neuroactive ligand-receptor interaction; Cytokine-cytokine receptor interaction; ECM-receptor interaction; Regulation of lipolysis in adipocytes; Wnt signaling pathway; Chemokine signaling pathway; Ras signaling pathway; Inflammatory mediator regulation of TRP channels; PI3K-AKT signaling pathway; GnRH signaling pathway; GABAergic synapse. Legend shows P-value from 1.00 to 0.00 and Count values 4, 7, 10, 13. The image G showing two volcano plots of differential metabolites. For both plots, x-axis label Log2(Fold Change) (unit unclear) and y-axis label minus Log10(P value) (unit unclear). Left plot statistics: Up 646, Down 407, Insignificant 2790; VIP legend values 0.5, 1.0, 1.5. Right plot statistics: Up 186, Down 95, Insignificant 3566; VIP legend values 0.5, 1.0, 1.5, 2.0, 2.5. The image H showing a four-set Venn diagram labeled Up I/R+LDHs-NBP vs I/R, Down I/R+LDHs-NBP vs I/R, Down I/R vs Sham, Up I/R vs Sham, with visible region values 102, 67, 13, 578, 363, 29, 55, 15 and multiple regions labeled 0 (some overlap values unclear). The image I showing a clustered heatmap of metabolites with a Group legend listing Sham, I/R and I/R+LDHs-NBP (value scale unit unclear). The image J showing a pathway enrichment bubble chart. x-axis label Rich Factor (unit unclear) with ticks 0.10, 0.15, 0.20, 0.25, 0.30. y-axis labels: Glycerophospholipid metabolism; Autophagy animal; Glycosylphosphatidylinositol GPI-anchor biosynthesis; Kaposi sarcoma-associated herpesvirus infection; Retrograde endocannabinoid signaling; Metabolism of xenobiotics by cytochrome P450; Glycerolipid metabolism; Lipid and atherosclerosis; Chemical carcinogenesis receptor activation; Cholesterol metabolism; Insulin resistance; Metabolic pathways; Thermogenesis; Fat digestion and absorption; Insulin phosphate metabolism (unclear); Nicotinate and nicotinamide metabolism; Phosphatidylinositol signaling system; Tyrosine metabolism; Regulation of lipolysis in adipocytes. Legend shows P-value from 1.00 to 0.00 and Count values 2, 16, 30, 44, 58.A multi-graph figure showing Venn, volcano, heatmap, network and bubble charts for genes and metabolites. (A and B) Gene selection and screening of core genes for the intersection of AKI and NBP genes. (C and D) Venn diagrams of overlapping differentially expressed genes in the three experimental groups, volcano plot of significantly differentially expressed genes between I/R and Sham, and volcano plot of significantly differentially expressed genes between I/R+LDHs-NBP and I/R. (E and F) Heatmap showing significantly differentially expressed genes in different samples and bubble chart of significant pathway enrichment analysis for all significant differentially expressed genes in I/R+LDHs-NBP (vs I/R). (G–J) A Venn diagram identified commonly differentially expressed metabolites across three groups, a heatmap visualized their expression patterns, and a bubble chart displayed significantly enriched pathways in the I/R+LDHs-NBP compared to the I/R. LDHs-NBP Activates the PI3K-AKT-Nrf2 Pathway in vivo to Alleviate Renal I/R To evaluate the antioxidant effect of LDHs-NBP and elucidate its underlying molecular mechanism, we measured oxidative stress markers and the expression of related proteins in renal tissues. The results indicated that, relative to the I/R group, both the I/R+NBP and I/R+LDHs-NBP treatments markedly increased SOD and T-AOC levels, while decreasing MDA concentration. Importantly, the LDHs-NBP group demonstrated a greater therapeutic effect compared to the NBP monotherapy group (Figure 4A), indicating that the LDH-based nanocarrier system substantially improved the antioxidant activity of NBP. Transcriptomic and metabolomic analyses collectively indicated that the PI3K-AKT pathway and glycerophospholipid metabolism might serve as key regulatory nodes in the present model. Therefore, the PI3K-AKT pathway is validated further. The immunohistochemical detection showed that LDHs-NBP markedly upregulated p-PI3K and p-AKT expression, and promoted the Nrf2 nuclear translocation, with more robust results than NBP alone (Figure 4B and C). LY294002, a recognized inhibitor of the PI3K-AKT pathway, is known for its suppression of p-AKT. The Western blot assay following LY294002 administration demonstrated that LDHs-NBP-induced AKT phosphorylation was significantly reversed. Nrf2 expression was also down-regulated (Figure 4D), which shows that the protective actions of LDHs-NBP are via the PI3K-AKT-Nrf2 pathway. Figure 4(A) Detection of SOD, MDA, and T-AOC in renal tissues by kits. (B) Immunohistochemical images. Scale bar: 100 μm. (C) Quantitative immunohistochemical images. (D) Protein expression and quantification. Data are presented as mean ± SD (n=3). *p < 0.05, **p < 0.01 and ***p < 0.001.The infographic figure is arranged in four labeled panels A to D, read from top to bottom. Panel A shows three bar charts with groups labeled: Sham, I/R, I/R+LDHs, I/R+NBP, I/R+LDHs-NBP. The y-axis labels are SOD (U/mg), MDA (mmol/gprot) and T-AOC (mmol/gprot). Significance markers above brackets use asterisks: asterisk, double asterisk and triple asterisk. Panel B shows immunohistochemical images in a grid with column headers: Sham, I/R, I/R+LDHs, I/R+NBP, I/R+LDHs-NBP. Row labels are p-PI3K, p-AKT and Nrf2. A scale bar label reads 100 μm. Panel C shows three bar charts labeled Positive Area of p-PI3K (percent), Positive Area of p-AKT (percent) and Positive Area of Nrf2 (percent), with the same group labels and asterisk significance markers. Panel D shows a Western blot with labels: p-PI3K, PI3K, p-AKT, AKT, Nrf2, β-Actin. To the right are three bar charts labeled Relative protein expression of p-PI3K/PI3K, Relative protein expression of p-AKT/AKT and Relative protein expression of Nrf2, with group labels including I/R+LDHs-NBP+LY294002 (unclear) and asterisk significance markers.An infographic figure with bar charts, tissue images and blots for SOD, MDA, T-AOC, p-PI3K, p-AKT and Nrf2. (A) Detection of SOD, MDA, and T-AOC in renal tissues by kits. (B) Immunohistochemical images. Scale bar: 100 μm. (C) Quantitative immunohistochemical images. (D) Protein expression and quantification. Data are presented as mean ± SD (n=3). *p < 0.05, **p < 0.01 and ***p < 0.001. Cell Proliferation, Uptake, and Lysosome Experiments We also investigated the impact of both LDHs, NBP, and LDHs-NBP on the proliferation of HK-2 (Figure 5A). Cells’ viability, which was observed to be the same across all LDHs concentrations after 24 hours of treatment, signifies that there is a lack of cytotoxic effects in these LDHs toward the HK-2 cells (Figure 5B). Among the test effective concentrations, 5 µg/mL LDHs-NBP greatly promoted cell proliferation compared to 5 µg/mL free NBP. On the basis of drug loading conversion, the drug concentrations of 4 µg/mL LDHs, 1 µg/mL NBP, and 5 µg/mL LDHs-NBP were selected for subsequent experiments. To investigate cellular uptake, FITC-labeled LDHs-NBP was incubated with HK-2 cells and imaged on a confocal laser scanning microscope: Fluorescence signals inside cells were shown as early as 1 hour after incubation, and persisted up to 4–24 hours, then became weaker probably because of continuous drug release, it suggested that LDHs might be able to keep treating inside the cells for a long time (Figure 5C). The Lysotracker Red stain shows a colocalization of green FITC-LDHs-NBP and red lysosome which indicates Lysosome mediated endocytosis (Figure 5D). AO Staining indicated that when compared with the control, LDHs-NBP treatment could reduce red fluorescence and increase green fluorescence. This suggests enhanced permeability of the lysosomal membrane (Figure 5E). The effect might help with getting out of the endosome and increase how much of the drug in the loaded thing can get into the main part of the cell. Figure 5(A) Schematic of the establishment of the H/R cell damage. (B) Comparative observation of the effects of different concentrations of LDH, NBP, and LDHs-NBP on HK-2 cell survival. (C) Confocal images of time-dependent cytoplasmic uptake of FITC-labeled LDHs-NBP; Scale bar: 20 μm. (D) The fluorescence colocalization images of LDHs-NBP (green) and lysosomes (red) indicate the lysosome escape. Scale bar: 50 μm. (E) AO for lysosome membrane permeabilization in HK-2 cells induced by LDHs-NBP; Scale bar: 50 μm. Data are expressed as mean ± SD (n=3), *p<0.05, **p<0.01and ***p<0.001.Section A shows the experimental setup: HK-2 cells are treated with a drug for 24 hours, followed by 12 hours of hypoxia and 4 hours of reoxygenation. Section B presents cell viability data. The left graph shows cell viability across various LDHs concentrations, indicating no cytotoxic effects. The right graph compares cell viability under different conditions, highlighting significant differences with asterisks. Section C displays confocal images of FITC-labeled LDHs-NBP uptake over time, from 0 to 48 hours. Section D shows fluorescence colocalization images of LDHs-NBP and lysosomes, indicating lysosome escape. Section E presents AO staining images, comparing H/R and H/R plus LDHs-NBP treatments, suggesting enhanced lysosomal membrane permeability. Scale bars are included in the images for reference.Infographic on HK-2 cell experiments with LDHs-NBP, showing cell viability, uptake and lysosome interaction. (A) Schematic of the establishment of the H/R cell damage. (B) Comparative observation of the effects of different concentrations of LDH, NBP, and LDHs-NBP on HK-2 cell survival. (C) Confocal images of time-dependent cytoplasmic uptake of FITC-labeled LDHs-NBP; Scale bar: 20 μm. (D) The fluorescence colocalization images of LDHs-NBP (green) and lysosomes (red) indicate the lysosome escape. Scale bar: 50 μm. (E) AO for lysosome membrane permeabilization in HK-2 cells induced by LDHs-NBP; Scale bar: 50 μm. Data are expressed as mean ± SD (n=3), *p<0.05, **p<0.01and ***p<0.001. LDHs-NBP Activates the PI3K-AKT-Nrf2 Pathway in vitro to Inhibit Oxidative Stress In order to observe the intracellular mechanism of LDHs-NBP, TEM was used to observe the ultrastructure of HK-2 mitochondria injured by H/R. H/R exposure caused major mitochondrial damage, including enlargement and dislocation of cristae; nevertheless, LDHs-NBP greatly maintained mitochondrial form and had more protection than NBP (Figure 6A). Functionally speaking, compared with NBP, LDHs-NBP showed greater improvement in SOD and T-AOC activity, MDA content, ROS level, cell apoptosis, and mitochondrial membrane potential. Furthermore, these protective effects were also abolished by pretreatment with PI3K inhibitor LY294002 (Figure 6B–E). Western blot analysis further confirmed that LDHs-NBP significantly activated the PI3K-AKT-Nrf2 pathway, whereas LY294002 pretreatment inhibited p-PI3K and p-AKT and substantially reduced Nrf2 (Figure 6F), suggesting that LY294002 interferes with Nrf2 activation, nuclear translocation, and downstream expression. These results suggest that LDHs-NBP might be able to keep cell redox balance by having the PI3K-AKT pathway turn on the Nrf2 pathway, which would stop there from being too much ROS and stop H/R causing problems with the mitochondria, oxidative stress, and when cells die off. Figure 6(A) TEM images of mitochondrial ultrastructure in. Scale bar = 500 nm. (B) Measurement of SOD, MDA, and T-AOC by a commercial assay kit. (C) Measurement of intracellular ROS levels by flow cytometry. (D) Flow cytometry of representative Annexin V/PI staining for measurement of apoptosis population. (E) JC-1 staining results on mitochondrial membrane potential. Scale bar: 50 μm. (F) The expression level and quantification by Western blot. Data results are expressed as mean ± SD. (n=3); *p < 0.05, **p < 0.01, and ***p < 0.001.Multi-panel infographic labeled A to F, arranged from top to bottom. A: TEM images titled Control, H/R, H/R+LDHs, H/R+NBP, H/R+LDHs-NBP. Scale bar = 500 nm. B: Three bar charts with y-axes and group labels: SOD (U/mg), MDA (nmol/prot), T-AOC (mmol/prot). X-axis groups: Control, H/R, H/R+LDHs, H/R+NBP, H/R+LDHs-NBP, H/R+LDHs-NBP+LY294002. Significance markers include asterisk, two asterisks and three asterisks. C: Flow cytometry histogram plot with y-axis Count and x-axis ROS level, showing curves for Control, H/R, H/R+LDHs, H/R+NBP, H/R+LDHs-NBP and H/R+LDHs-NBP+LY294002. D: Annexin V FITC versus PI flow cytometry dot plots for Control, H/R, H/R+LDHs, H/R+NBP, H/R+LDHs-NBP and H/R+LDHs-NBP+LY294002, plus bar charts labeled Apoptosis (percent) and The intensity of ROS. E: JC-1 staining image rows labeled Aggregates, Monomers and Merge for the same six groups, plus a bar chart labeled JC-1 aggregates to monomers ratio. F: Western blot bands labeled p-PI3K, PI3K, p-AKT, AKT, Nrf2 and beta-Actin, with bar charts labeled Relative protein expression of p-PI3K/PI3K, Relative protein expression of p-AKT/AKT and Relative expression of Nrf2. Data results are expressed as mean plus or minus SD. (n=3); asterisk < 0.05, two asterisks < 0.01 and three asterisks < 0.001.Infographic of HK-2 assays comparing Control and H/R treatments on mitochondria, ROS, apoptosis and proteins. (A) TEM images of mitochondrial ultrastructure in. Scale bar = 500 nm. (B) Measurement of SOD, MDA, and T-AOC by a commercial assay kit. (C) Measurement of intracellular ROS levels by flow cytometry. (D) Flow cytometry of representative Annexin V/PI staining for measurement of apoptosis population. (E) JC-1 staining results on mitochondrial membrane potential. Scale bar: 50 μm. (F) The expression level and quantification by Western blot. Data results are expressed as mean ± SD. (n=3); *p < 0.05, **p < 0.01, and ***p < 0.001. Discussion This paper aimed to solve the problems of poor aqueous solubility and low bioavailability of NBP by constructing LDH-based nanocomposites, LDHs-NBP, to improve the pharmacodynamic effect of NBP. The protective mechanisms of LDHs-NBP on AKI due to I/R were investigated systematically. Main Conclusions: Highly drug-loaded (around 24%) and stable LDHs-NBP nanocomplexes were successfully constructed. The superior renal protective efficacy of LDHs-NBP nanocomplex was observed against NBP in both in cell and in animal models. The renal function recovery and reduction of tissue pathological and oxidative stress damages of renal tissues were significantly improved, multi-omics and biological experiments indicated that activation of the PI3K-AKT-Nrf2 pathway was a reason for LDHs-NBP protective effect. The PI3K-AKT signaling cascade plays a critical role in regulating diverse pathophysiological processes such as metabolism, oxidative stress responses, and immune-related inflammation.20–22 Upon activation, the pathway enhances nuclear translocation of the transcription factor Nrf2, which then mediates protection against oxidative damage. Once in the nucleus, Nrf2 interacts with antioxidant response elements (AREs), inducing the expression of antioxidant genes, lowering ROS levels, and strengthening the cellular defense system to mitigate oxidative damage.23 Previous studies have demonstrated that Dendrobium officinale extract mitigates renal injury through the PI3K/Akt/Nrf2/HO-1 pathway, while arbutin exerts protective effects against LPS-AKI by suppressing inflammation and apoptosis via activation of the PI3K/Akt/Nrf2 cascade.24–27 Besides this, NBP has also been shown to get rid of cerebral IRI by turning on the PI3K/Akt pathways,28–32 and to improve diabetic kidney damage by curbing too much scarring and podocyte cell death. Additionally, NBP has been shown to mitigate renal I/R by activating the Nrf2/HO-1 signaling pathway, and suppressing the NOD2/MAPK/NF-κB pathway.9–12 In summary, these results support the idea of PI3K-AKT signals being activated and downstream Nrf2 signals providing antioxidant, anti-inflammatory, and anti-apoptotic effects in different types of kidney disease, and can also provide new treatment ideas and strategies for the development of reno-protective drugs. In recent years, nanomedicine delivery systems have been applied in the treatment of kidney diseases.33–38 Some scholars have developed ROS-responsive, convertible, and tri-targeted NBP nanotherapies and NBP-loaded systems according to CeO2 nanoparticles (NBP-CeO2 NPs) for the treatment of ischemic stroke.39,40 This shows the possibility of NBP nanotherapies for kidney treatment, bringing different views for the prevention and treatment of AKI. Compared with other nanotechnology materials, the novel nanomaterial LDH has the advantages of its unique layered structure and adjustable surface properties in terms of drug loading, protection, and controlled release of drugs.41,42 According to dynamic light scattering and zeta potential testing, both show that the obtained LDHs-NBP is suitable in terms of nanosized and surface potential so as for improvement in the nephrotoxicity, cellular uptake is made possible, thus forming a ground for better in vivo bioavailability and efficacy of NBP. Efficacy evaluation was also done in the I/R model and H/R treated cell model; the results show LDHs-NBP has better protective effects than NBP. It directly decreases on level of SCr and BUN, alleviates tissue pathological lesions, repairs mitochondrial ultrastructure, improves oxidative stress indexes such as SOD, MDA, T-AOC, etc., inhibits apoptosis, eliminates ROS, and restores mitochondrial membrane potential. All these results point to the fact that LDHs as nanocarriers can remarkably improve NBP’s effectiveness and have distinct strengths for regulating oxidative stress.43–45 The omics results and others suggest that LDHs-NBP may exert protective effects through the PI3K-AKT-Nrf2 pathway. LDHs-NBP alleviates oxidative stress damage, enhances the levels of phosphorylated PI3K and AKT, facilitates Nrf2 nuclear translocation, and upregulates Nrf2 expression; these effects are abolished by LY294002. These findings suggest that the kidney protective effects of LDHs-NBP may be mediated through the PI3K-AKT-Nrf2 pathway, offering a novel theoretical basis for drug development. Although this study obtained positive results, there are still some flaws. Firstly, the renal targeting mechanism of LDHs-NBP has not been fully elucidated, and both its targeting specificity and the biodistribution of the nanocarriers need further verification. The second point is that the interactions between the PI3K-AKT-Nrf2 signaling pathway and other signaling pathways, as well as the activation levels of this pathway in other organs, have not yet been explored. Also, long-term safety and pharmacokinetic behavior have not been systematically assessed, which is a problem that most nanomedicines encounter during clinical translation. According to the above findings and restrictions, the following can be done in future research: further investigation of its renal targeting mechanism and distribution characteristics using in vivo imaging or elemental tracing is needed to improve treatment accuracy; systematically assess the pharmacokinetic characteristics and long-term safety of the nanomedicine LDHs-NBP to provide a basis for its clinical translation; study the combination application of nanosystem with other therapies (such as remote ischemic preconditioning or targeted ferroptosis therapy) to broaden its applications for renal I/R and related diseases. Conclusion In this study, we have successfully developed LDHs-NBP nanocomposites and proven that they can improve renal function through the PI3K-AKT-Nrf2 pathway, decrease oxidative stress in the renal tissue, and mitigate I/R kidney injury. Also, LDHs-NBP greatly promoted the viability and scavenging abilities of the HK-2 after the H/R injury, lowered the rate of cell apoptosis, hastened the clearance rate of ROS, and rebuilt the mitochondrial membrane potential (Figure 7). The LDHs-NBP nanocomposite system established in this work not only presents a novel strategy for enhancing the bioavailability of NBP and preventing I/R-induced AKI, but also provides valuable experimental evidence and theoretical insights for future research and clinical translation of PI3K-AKT-Nrf2 pathway-targeted interventions in oxidative stress-related renal diseases. Figure 7Schematic diagram of the mechanism by which LDHs-NBP nanocomposites alleviate acute I/R renal injury.LDHs and NBP combine to form LDHs-NBP, which targets ischemia-reperfusion in the kidney, reducing ROS. In the HK-2 cell cytoplasm, GFR activates PI3K through p85 and p110, converting PIP2 to PIP3. This activates AKT, which then activates Nrf2. Nrf2 translocates to the nucleus, binding to ARE, reducing apoptosis, ROS and mitochondrial membrane potential loss (Δψm).Diagram of LDHs-NBP protecting against renal ischemia-reperfusion injury via PI3K-AKT-Nrf2 pathway.Abbreviations: LDHs, layered double hydroxides; NBP, Dl-3-n-butylphthalide; ROS, reactive oxygen species; GFR, growth factor receptor; PIP2, phosphatidylinositol 4,5-bisphosphate; PIP3, phosphatidylinositol 3-phosphate; PI3K, phosphoinositide 3-kinase; AKT, protein kinase B; Nrf2, Nuclear factor-erythroid 2 related factor 2; ARE, Antioxidant Response Element. Schematic diagram of the mechanism by which LDHs-NBP nanocomposites alleviate acute I/R renal injury.